XARELTO®: Extended treatment and reduction in the risk of recurrence in deep vein thrombosis (DVT) and pulmonary embolism (PE)

XARELTO® helps reduce the risk of recurrent DVT/PE*1-7

DVT/PE DOSING Once daily for extended treatment after 6 months of initial treatment

DVT/PE EFFICACY Superior reduction in recurrent DVT/PE vs aspirin in extended treatment1

DVT/PE SAFETY Major bleeding rates as low as aspirin in extended treatment1

DVT/PE CLINICAL TRIALS The EINSTEIN CHOICE trial studied extended treatment in patients with DVT/PE1

VTE PLATFORM 6 indications to treat and help protect from a VTE—both inpatient and outpatient*1-7

JANSSEN CAREPATH XARELTO® Savings Program

FORMULARY FINDER Coverage for your patients

Extended DVT/PE Resources

DOSING ACROSS INDICATIONS Condition-specific dosing for XARELTO®

EINSTEIN CHOICE REPRINT EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism

DVT/PE PATIENT WELCOME KIT Your patient’s guide to starting treatment

View all resources

*The decision regarding initiation setting should be based on the prescriber's clinical judgment.

DVT = deep vein thrombosis; PE = pulmonary embolism; VTE = venous thromboembolism.

References: 1. Weitz JI, Lensing AWA, Prins MH, et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376(13):1211-1222. 2. The EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1297. 3. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510. 4. Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-2775. 5. Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31-39. 6. Lassen MR, Ageno W, Borris LC, et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-2786. 7. Cohen AT, Spiro TE, Büller HR, et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6):513-523.